Perioperative Pembrolizumab in Japanese Participants With Early-Stage NSCLC: Subgroup Analysis From KEYNOTE-671
Masahiro Tsuboi, Hisashi Saji, Morihito Okada, Norihiko Ikeda, Kazuya Takamochi, Kenji Sugio, Yoshitsugu Horio, Fumihiro Tanaka, Wataru Nishio, Satoshi Muto, Hidehito Horinouchi, Heather Wakelee, Shirong Han, Tomoko Mori, Steven M Keller, Terufumi Kato · 2026
Read Perioperative Pembrolizumab in Japanese Participants With Early-Stage NSCLC: Subgroup Analysis From KEYNOTE-671 by Masahiro Tsuboi, Hisashi Saji, Morihito Okada, Norihiko Ikeda, Kazuya Takamochi, Kenji Sugio, Yoshitsugu Horio, Fumihiro Tanaka, Wataru Nishio, Satoshi Muto, Hidehito Horinouchi, Heather Wakelee, Shirong Han, Tomoko Mori, Steven M Keller, Terufumi Kato (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13595008.txt.
Description
Tsuboi leads a large team reporting Japanese results from a lung cancer trial, in work from twenty twenty-six. The global trial tested pembrolizumab, an immune drug, given around surgery for early stage lung cancer. The main trial found better survival with the drug plus chemotherapy.
Japanese patients with untreated stage two or three disease were split evenly. One group got the drug with chemo before surgery, then the drug after. The other got a placebo in the same slots. Main measures were time without a bad event and overall survival. Subgroup results like this show whether global gains hold in a specific national group.
Catalog record
| CREATOR | Masahiro Tsuboi, Hisashi Saji, Morihito Okada, Norihiko Ikeda, Kazuya Takamochi, Kenji Sugio, Yoshitsugu Horio, Fumihiro Tanaka, Wataru Nishio, Satoshi Muto, Hidehito Horinouchi, Heather Wakelee, Shirong Han, Tomoko Mori, Steven M Keller, Terufumi Kato |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |